Gilead to acquire Interius BioTherapeutics for $350M, sees dilution

Kite, a Gilead (GILD) company, announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350M. Interius’s team and operations will integrate into Kite’s established research team, creating a center of excellence in Philadelphia to accelerate the development of next-generation in vivo therapies. Under the terms of the acquisition agreement with Interius, Kite will acquire all of the outstanding share capital of Interius for a total of $350M in cash consideration, subject to customary adjustments, which is payable at closing. This transaction with Interius is expected to reduce Gilead’s GAAP and non-GAAP 2025 EPS by approximately $0.23-$0.25. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.